ReviewFrontiers in oncology2026
Synthetic short RNA in cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small RNAs play an important role in many biological processes. They vary widely in size and form, including single- and double-stranded RNAs. Synthetic short RNAs are very powerful tools for modulating or intervening in cellular biology, and many types of artificial oligonucleotides have been explored to mimic small RNAs. For instance, small interfering RNA (siRNA) hybridizes with target RNA to decrease protein expression by promoting RNA degradation. An aptamer binds to target molecules through non-hybridizing nucleotide-molecule interactions. Furthermore, recent findings suggest that synthetic nucleic acids utilizing extracellular mRNA sequences act on immune cells expressing RNA-binding molecules, resulting in anti-tumor effects. These molecular specificities are generated by the primary sequence of the nucleic acid and its chemical modifications. These features are applied to anti-tumor drug discovery. In this review, we summarize the basics of synthetic short RNAs and discuss their anti-tumor potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.